How Should You Treat/Assess Non-culprit Disease? - Dr. Justin Davies
Simple Education
1,137 videos
Summary
Justin Davies details the assessment and treatment of bystander CAD in ACS
- The negative prognostic impact of multi vessel disease in STEMI
- Theoretical pros and cons of both treating and...
Summary
Justin Davies details the assessment and treatment of bystander CAD in ACS
- The negative prognostic impact of multi vessel disease in STEMI
- Theoretical pros and cons of both treating and deferring non-culprit vessels in ACS
- The concept of "vulnerable plaque"
- Previous guidelines recommendations strongly discouraged treating non-culprit arteries in STEMI (class III recommendation in 2013); now upgraded to Class IIb
- Summary of RCT evidence available on this topic: PRAMI, CvLPRIT, DANAMI
- Intracoronary imaging with IVUS and OCT to characterise plaque composition, vessel characteristics and luminal area
- Future RCTs currently ongoing that will provide more data to guide us in this field
About Simple Education
Simple Education, is a leading provider of coronary physiology and intracoronary imaging courses to aid treatment of complex coronary artery disease.
Speakers
Dr Justin Davies is a honorary interventional cardiologist at Hammersmith Hospital, Imperial College NHS Trust,...
Dr Justin Davies is a honorary interventional cardiologist at Hammersmith Hospital, Imperial College NHS Trust, London. After training at Imperial College, he won a prestigious BHF research fellowship to study arterial haemodynamics. Since then he has continued to work on the development of mathematical algorithms to aid understanding of large artery physiology and to develop new tools to assess arterial disease. The holder of several patents, he has published widely in the field of hypertension, coronary and large artery physiology and is the winner of many national and international awards. He has several international collaborations, and is the developer of iFR and the co-principal investigator of the ADVISE studies, the DEFINE-FLAIR, ORBITA and DEFINE-PCI studies. Justin also has an interest in renal denervation, and has lead the first-in-man studies to evaluate the safety of this technique to patients with chronic systolic heart failure (REACH studies).
Related Videos
Start a conversation